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A candidate genetic risk 
factor for vascular disease: 
a common mutation in 
methylenetetrahydrofolate 
reductase
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L.P. van den Heuvel2 & R. R ozen1
Hyperhomocysteinaemia has been identified as a 
risk factor for cerebrovascular, peripheral vascular 
and coronary heart disease1'4. Elevated ieveis of 
plasma homocysteine can result from genetic or 
nutrient-relateddisturbancesinthetrans-sutphuration 
or re-methyiation pathways fo r homocysteine 
metabolism1,5-7. 5,10-Methylenetetrahydrofolate 
reductase (MTHFR) catalyzes the reduction of 5,10- 
methylenetetrahydrofolate to 5 -m ethy ite tra - 
hydrofolate, the predominant circulatoryform offolate 
and carbon donor for the re-m ethylation of 
homocysteineto methionine. Reduced MTHFR activity 
with a thermolabile enzyme has been reported in 
patients with coronary and peripheral artery 
disease5,6. We have identified a common mutation 
in MTHFR which alters a highly-conserved amino 
acid; the substitution occurs at a frequency of 
approximately 38% of unselected chromosomes. 
The mutation in the heterozygous or homozygous 
state correlates with reduced enzyme activity and 
increased thermofability in lymphocyte extracts; in 
vitro expression of amutagenized cDNA containing 
the mutation confirms its effect on thermolability of 
MTHFR. Finally, individuals homozygous for the 
mutation have significantly elevated plasma 
homocysteine levels. This mutation in MTHFR may 
represent an important genetic risk factor in vascular 
disease.
Severe MTHFR deficiency, the m ost com m on inborn  
error of folate metabolism, results in hyperhom o“ 
cysteinaemia, homocystinuria, and hypomethioninaemia. 
Patients with severe MTHFR deficiency (0-20%  residual 
-activity in cultured fibroblasts) present in infancy or 
adolescence with developmental delay, motor and gait 
dysfunction, seizures, psychiatric disturbances and other 
neurological abnormalities; they are also at risk for vascular 
complications8. Individuals with 50% residual activity, due 
to a thermolabile form of the reductase, were first reported 
in approximately 17% of 212 North American patients with 
coronary artery disease5. A recent study of the Netherlands 
population identified the thermolabile variant in different 
forms of premature vascular disease6, and estimated its 
incidence to be 7% of vascular patients. The presence o f a 
thermolabile MTHFR is predictive o f coronary artery 
stenosis, independent of other risk factors, such as age, 
smoking, hypercholesterolaemia and hypertension9.
Our recent isolation o f a cDNA for hum an MTHFR10 
has enabled us to identify nine mutations in this gene, in 
the severely-deficient group of patients, by SSCP analysis
and direct sequencing o f PCR fragments10,11. Using the 
same procedures, we identified a C to T substitution at 
nucleotide (nt) 677, which converts an alanine to a valine 
residue (Fig, la). This alteration creates a H infl site (Fig. 
lb ) ,  which was used to screen 114 unselected French 
Canadian chromosomes; the allele frequency o f the 
substitution was 0.38. The frequency o f the three genotypes 
were as follows: 37%; + /- , 51%; and + /+ , 12% (+  
indicates the presence o f the H infl site and a valine residue). 
As these individuals were not examined clinically or 
biochemically, they cannot be considered as a control group. 
W e next performed genotypic analysis and measured 
enzyme activity and thermolability in a total of40 lymphocyte 
pellets from patients with premature vascular disease and 
controls (Table 1). W e selected 13 vascular patients from 
our previous study, among whom  five were considered to 
have thermolabile MTHFR6. From a large reference group 
o f 89 controls, we studied all seven individuals who had 
thermolabile MTHFR, and selected at random an additional 
20 controls with normal MTHFR from the same reference 
group. The mean MTHFR activity for individuals 
homozygous for the Ala to Val substitution (+/+) was 
approximately 30% of the mean activity for ( - / - )  individuals. 
Heterozygotes had a mean MTHFR activity o f 65% 
compared to ( - / - )  individuals, intermediate between values 
for ( - / - )  and (+ /+) individuals. The ranges o f activities 
showed some overlap for the heterozygous and ( - /- )  
genotypes, but homozygous (+ /+ ) individuals showed 
virtually no overlap with the other two groups. A one-way
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Fig. 1 Sequence change and restriction enzyme analysis for the 
alanine to valine substitution, a, Sequence of two individuals, a 
homozygote for the alanine residue and a homozygote for the valine 
residue. The antisense strands are depicted. The primers for analysis 
of the A -*V  change are: 5'-TGAAGGAGAA GGTGTCTGCG GGA-3' 
(exonic) and 5-AGGACGGTGC GGTGAGAGTG~3'(intronic); these 
primers generate a fragment of 198 bp, b, The substitution creates a 
H/nfl recognition sequence which digests the 198 bp fragment into 175 
and 23 bp fragments; the latter fragment has been run off the gel. All 
three possible genotypes are shown.
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Table 1 Correlation between MTHFR genotype and enzyme 
activity, thermolability and plasma homocysteine level
Genotype
+ /- +/+
n=19 n=9 n=12
Specific activitya>b 22.9±1.7 15.0+0,8 6.9±0.6
(nmol CH20/mg protein/hr) (11.8-33.8) (10.2-18.8) (2.6-10.2)
Residual activity 66.8+1.5 56.2+2.8 21,8±2.8
after heating“’* (%) (55-76) (41-67) (10-35)
Plasma homocysteinea,c 12.6+1.1 13.8±1.0 22.4±2.9
(j^M)(after fasting) (7-21) (9.6-20) (9.6-42)
Plasma homocysteine3,0 41.3±5.0d 41+2.8 72.6±11.7a
(|iM)(post-methionine load) (20.9-110) (29.1-54) (24.4-159)
Enzyme activity and plasma homocysteine were determined as previously reported6. Each 
value represents mean ± standard error. The range is given in parentheses below the mean. 
aone-way anova P<.01. bpaired t test for all combinations P<.01. ^paired t test P<.05 for +/+ 
group versus + /-  group or - / -  group; P>.05 for + /-  versus - / -  group. dn=18, en=11.
analysis o f variance yielded a P  value <.0001; a pairwise 
Bonferroni t test showed that all three genotypes were 
significantly different with P<0.01 for the three possible 
combinations.
The three genotypes were all significantly different (P<.01) 
with respect to enzyme thermolability. The mean residual 
activity after heat inactivation (5 min at 46 °C) was 67% ( -  
/ - ) ,  56% (+ /- )  and 22% (+/+). While the degree of 
thermolability overlaps somewhat for ( - /- )  individuals and 
heterozygotes, individuals with two mutant alleles had a 
distinctly lower range. Every individual with the (+/+) 
genotype had residual activity <35% after heating, and 
specific activity <50% of that o f the ( - /- )  genotype.
Fasting homocysteine levels in (+/+) individuals were 
almost twice the value for (+ /-) and (- /- )  individuals. The 
differences among genotypes for plasma homocysteine were 
maintained when homocysteine was measured following 
six hours of methionine loading. A one-way anova yielded 
a P<.01 for the fasting and post-methionine homocysteine 
levels. A p airwise Bonferroni t test showed that homozygous 
mutant individuals had significantly elevated homocysteine
levels (P<.05), compared to either (+ /-) or ( - /- )  individuals.
We have used the original MTHFR cDNA (1.3 kb) to 
isolate a 2.2 kb cDNA, which contained an additional 900 
bp at the 3' end; the latter contained a termination codon, 
100 bp o f 3' UTR and a poly A tail (GenBank#U09806). 
The open reading frame o f 1980 bp predicts a protein of 
74.6 kDa. The purified porcine liver enzyme has been 
shown to have subunits of 77 kDa12. Western analysis (Fig.
2 a) o f several human tissues and o f porcine liver reveals a
i
polypeptide o f 77 kDa, as well as an additional polypeptide 
of approximately 70 kDa in human fetal liver and in 
porcine liver, suggesting the presence o f isozymes.
The wild-type cDNA and a m utagenized cDNA, 
containing the Ala to Val substitution, were expressed in 
E, coli to yield a protein of approximately 70 kDa (Fig. 2 a), 
which co-migrates with the smaller polypeptide mentioned 
above. Treatment of extracts at 46 °C for five minutes 
revealed that the enzyme containing the substitution was 
significantly more thermolabile than the wild-type enzyme 
(P<.001; Fig. 2b). The expression experiments were not 
designed to measure differences in specific activity before 
heating, since variation in efficiencies o f expression could 
contribute to difficulties in interpretation. Curiously 
though, the specific activity for the mutant construct was 
higher in both experiments. It is possible that the mutant 
protein has increased stability in E. coli, or that inclusion 
bodies in our extracts contributed to differences in recovery 
of properly-assembled enzyme.
The alanine residue is conserved in porcine MTHFR 
and in the corresponding bacterial m etF genes10. We have 
also observed a region of hom ology in the human 
dihydrofolate reductase (DHFR) gene11, although the 
alanine residue itself is not conserved; this region of 
amino acids 130-149 of DHFR contains Thrl36 which 
has been implicated in folate binding o f human DHFR13. 
This region in MTHFR might also be involved in folate 
binding and the enzyme maybe stabilized in the presence 
o f folate. This hypothesis is compatible with the well- 
documented influence of folate on homocysteine levels7,14
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Fig. 2 Expression analysis of MTHFR in E.coli. a, Western blot of bacterial extracts and tissues. Two |ig of bacterial extract protein was used for lanes 1-3. The tissues 
(lanes 4-6) were prepared by homogenizatlon in 0.25 M sucrose with aprotinln and leupeptin, followed by sonication on ice. The extracts were spun for 15 min In a 
microcentrifuge at 14,000g and 100 \iq of supernatant protein was used for western analysis, h, human; p, porcine, b, Thermolability assay of bacterial extracts. Two 
separate experiments (with 3-4  replicates construct experiment) were performed to measure thermostable activity of the wild-type and mutagenized MTHFR cDNAs. 
The values shown represent mean ± standard error for each experiment, as % of residual activity after heating. The means of the specific activities before heating 
(expressed as nmol formaldehyde/hr/mg protein) were as follows: 3.8 and 5.3 (Exp. 1) and 6.2 and 7.5 (Exp. 2) for MTHFR and MTHFR A->V, respectively.
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and with the reported correction of mild 
hyperhomocysteinaemia by folic acid in individuals with 
premature vascular disease14 and thermolabile MTHFR15.
Our data have identified a common genetic change in 
MTHFR which results in thermolability; our experiments 
do not directly address the relationship between this 
change and vascular disease. Nonetheless, this mutation 
represents a diagnostic test for evaluation of MTHFR 
thermolability in hyperhomocysteinaemia. Large case- 
control studies are required to evaluate the frequency of this 
genetic change in various forms of occlusive arterial disease 
and to examine the interaction between this genetic marker 
and dietary factors, such as folate intake. Well-defined 
populations need to be examined, as the limited data set 
thus far suggests that population-specific allele frequencies 
may exist. More importantly, however, the identification of 
a candidate genetic risk factor for vascular disease, which 
may be influenced by nutrient intake, represents a critical 
step in the design of appropriate therapies for the 
homocysteinaemic form o f arteriosclerosis.
Methodology
Mutation identification. Primers were designed from the cDNA 
sequence to generate 250-300bp fragments which overlapped 50—75 
bp at each end. When PCR amplification o f human genomic DNA 
yielded larger fragments than expected for the coding region alone, 
these fragments were presumed to contain introns and weresequenced 
directly (Cycle Sequencing kit, GIBCO). Intronic primer squences 
were obtained with this strategy. PCR products were analysed by a 
non-radioactive SSCP protocol as described10. Fragments showing a 
shift on SSCP gels were sub cloned into Bluescript and sequenced 
(Sequenase kit, USB), To confirm the sequence changes, a new PCR 
was performed with genomic DNA; the PCR product was digested 
with Hinfi and analysed by polycrylamide gel electrophoresis.
Clinical material. To determine the frequency of the A~»V mutation, 
DNA from 57 individuals from Quebec was analysed by PCR and 
restriction digestion. The individuals, all French Canadian, were not 
examined clinically or biochemically. The 40 individuals analysed in 
Table 1 have been described6, Of the 13 cardiovascular patients, eight 
had cerebrovascular arteriosclerosis and five had peripheral 
arteriosclerosis, Five had thermolabile MTHFR while eight had 
thermostable MTHFR (>33% residual activity after heating). Controls 
and patients were all Dutch-Caucasian, between 20-60 years of age. 
None of these individuals used vitamins which could alter 
hom ocysteine levels. Enzyme assays and hom ocysteine  
determinations have also been reported6.
Constructs for expression analysis. A human colon carcinoma 
cDNA library (gift of Nicole Beauchemin, McGill University) was 
screened by plaque hybridization with the original 1.3 kb cDNA10 to 
obtain additional coding sequences. A cDNA of 2.2 kb was isolated, 
which contained 900 additional bp at the 31 end (Genbank accession
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number U09806). Sequencing was performed on both strands for 
the entire cDNA. Additional 5' sequences (800 bp) were obtained 
from a human kidney cDNA library (Clontech) but these sequences 
did not contain additional coding sequences and were therefore used 
for the PCR~based mutagenesis only (see below) and not for the 
expression analysis. The two cDNAs (2.2kband800bp) were ligated 
using the EcoRl site at nt 19 9 and inserted into Bluescript (Stratagene), 
The 2.2 kb cDNA was subcloned into the expression vector pTrc99A 
(Pharmacia) using the Ncol site at nt 11 and the Xbfll site in the 
polylinker region of both vectors. Sequencing was performed across 
the cloning sites to verify the wild-type construct.
PCR-based mutagenesis» using the cDNA-containing Bluescript 
vector as template, was used to create the A to V mutation identified16. 
Vent polymerase (NEB) was used to reduce PCR errors. The following 
primers were used: primer 1, bp -200 to -178, sense; primer 2, bp 667 
to 687, antisense, containing a mismatch, A, at nt 677; primer 3,667 
to 687, sense, containing a mismatch, T> at nt 677; primer 4, bp 1092 
to 1114, antisense. PCR was performed using primers 1 and 2 to 
generate a product of 887 bp, and using primers 3 and 4 to generate 
a product o f  447 bp. The two PCR fragments were isolated from a
1.2% agarose gel by Geneclean (BIO 101). A final PCR reaction, using 
primers 1 and 4 and the first two PCR fragments as template, was 
performed to generate a 1.3 kb band containing the mutation. The 1.3 
kb fragment was digested with Ncol and MscI, and inserted into the 
wild-type cDNA-containing expression vector by replacing the 
sequences between the Ncol site at bp 11 and the Mscl site at bp 943, 
The entire replacement fragment and the cloning sites were sequenced 
to verify that no additional changes were introduced by PCR.
Expression analysis. Overnight cultures o f JM105 containingvector, 
wild-type or mutagenized MTHFR cDNA were grown at 37 °C, in 2 
X YT media with ,05 mg ml"1 ampicillin. Fresh 10 ml cultures o f  each 
were inoculated with approximately 50 |il of overnight cultures and 
grown at 37 °C to an O.D. of 1 at 420 nM. Cultures were then induced 
for 2 h with 1 mM IPTG and pelleted. The cells were resuspended in 
TE buffer with 2 |lg ml-1 aprotinin and leupeptin (3.5 x wet weight of  
cells). Cell suspensions were sonicated on icefor3xl5sand centrifuged 
for 30 min at 4 °C to pellet cell debris and unlysed cells, The supernatant 
was removed and assayed for protein concentration with the Bio-Rad 
protein assay. Western analysis was performed using the Amersham 
ECL kit with antiserum generated against purified porcine liver 
MTHFR12. Enzymatic assays were performed by established 
procedures17; thermolability was assessed by pre-treating the extracts 
at 46 °C for 5 min before determining activity. Specific activities (nmol 
formaldehyde/h/mg protein) were calculated for the 2 cDNA- 
containing constructs after subtraction of the values obtained with 
vector alone (to subtract background E.coli MTHFR activity).
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